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ABSTRACT
Purpose: To investigate human beta-defensins (HBDs) and cathelicidin LL-37 
(LL-37) expressions in patients with pterygium.
Methods: In this retrospective consecutive case series, 26 pterygium specimens 
and 15 normal conjunctival specimens of 15 control subjects were in vestigated. 
Expressions of HBD-1, HBD-2, HBD-3, and LL-37 were assessed using immuno-
histochemical staining. A brown color in the cytoplasm and/or nuclei of epi-
thelial cells indicated positive staining for HBDs and LL-37. For each antibody, 
the intensity of the reaction (negative [-], weak [1+], moderate [2+], or strong 
[3+]) was determined to describe the immunoreactions. 
Results: The median age was 52 years in both groups. There were no significant 
differences in age and sex between the groups (p=0.583, p=0.355, respectively). 
Of the 26 pterygium specimens, 15 (57.7%) (14 weak, 1 moderate staining) showed 
HBD-2 expression, which was not observed in any of the control specimens. One 
(3.8%) pterygium and one (6.7%) control specimen demonstrated weak staining 
for HBD-3. HBD-2 expression was significantly higher in the pterygium specimens 
than in the controls (p=0.002). None of the tissue specimens had positive staining 
for HBD-1 or LL-37 in either group (both; p=1.00). 
Conclusions: HBD-2 expression was higher in pterygium specimens than in the 
controls. HBD-2 expression that might be stimulated by inflammatory cytokines 
may be related to inflammation and fibrovascular proliferation and may play a 
role in pterygium pathogenesis.
Keywords: Cathelicidins; Beta-defensins; Immunohistochemical; Inflammation; 
Pterygium/pathology
RESUMO
Objetivo: Investigar as expressões beta defensinas humanas (HBD) e catelicidina 
em pacientes com pterígio. 
Métodos: Nesta série de casos retrospectivos consecutivos, 26 espécimes de pterígio e 
15 espécimes conjuntivais normais de 15 indivíduos controle foram investigados. 
As expressões de HBD-1, HBD-2, HBD-3 e catelicidina (LL-37) foram avaliadas por 
coloração imuno-histoquímica. Uma cor castanha no citoplasma ou nos núcleos 
de células epiteliais foi definida como coloração positiva para HBDs e LL-37. Para 
cada anticorpo foi determinada a intensidade da reação (negativo [-], fraco [1+], 
moderado [2+] ou forte [3+]) para descrever as imunoreações. 
Resultados: A idade média foi de 52 anos em ambos os grupos. Não houve dife-
rença significativa entre os grupos em termos de idade e sexo (p=0,583, p=0,355, 
respectivamente). Das 26 amostras de pterígio, 15 (57,7%) (14 fracas e 1 moderada) 
demonstraram a expressão de HBD-2 enquanto não foi encontrada em nenhum dos 
espécimes de controlo. Um dos pterígios (3,8%) e um dos espécimes de controlo (6,7%) 
demonstraram fraca coloração para HBD-3. A expressão de HBD-2 foi significati-
vamente maior nos espécimes de pterígio do que nos controles (p=0,002). Nenhum 
dos espécimes de tecido apresentou coloração positiva para HBD-1 ou LL-37 em 
ambos os grupos (ambos p=1,00). 
Conclusão: Encontramos aumento da expressão de HBD-2 em espécimes de pte rígio 
em relação aos controles. A expressão de HBD-2 que pode ser estimulada por citocinas 
inflamatórias pode estar relacionada com inflamação e proliferação fibrovascular e 
pode desempenhar um papel na patogênese do pterígio.
Descritores: Catelicidinas; Beta defensinas; Imunohistoquímica; Inflamação; Pte-
rígio/patologia
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INTRODUCTION
Pterygia develop from the growth of fibrovascular tissue of bulbar 
conjunctiva into the interpalpebral area of the cornea. Although the 
pathogenesis is not completely understood, oxidative stress, immu-
nogenic mechanisms, anti-apoptosis, extracellular matrix remode-
ling, angiogenesis, viral infections, and genetic factors are considered 
to be contributing factors. Epidemiological studies have shown that 
chronic ultraviolet exposure has a major role in pterygium pathoge-
nesis(1). Ultimately, chronic inflammation due to some or all of the 
above factors probably causes fibrovascular proliferation. Cytokines, 
growth factors, stem cell factors, and pro-angiogenic factors may 
all have a role in inflammation and fibrovascular proliferation of 
pathogenesis of pterygium(1). It has been shown that the expression 
of human alpha-defensin, which is an antimicrobial peptide (AMP), 
is increased in the tears of patients with pterygia because of fibro-
vascular proliferation or associated inflammation(2). In addition, it has 
been reported that some AMPs may be stimulated by proinflamma-
tory cytokines, such as interleukin (IL)-1 alpha, IL-1 beta, and tumor 
necrosis factor-alpha(3,4).
AMPs provide one of the defense mechanisms that are part of 
the innate immune response against exogenous pathogens. AMPs 
are divided into two major groups: defensins and cathelicidins. Hu-
man defensins are also divided into two groups: alpha and beta(5). 
Human beta-defensins (HBD) have four subgroups (1 to 4) and are 
primarily expressed in epithelial tissues. However, HBD-1 and -2 are 
also present in immune cells, such as monocytes, macrophages, and 
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dendritic cells(6). It has been shown that the expressions of HBD-2 
and -3 are stimulated by some cytokines(3-7). Although HBD-1 and -3 
have been found in healthy corneal and conjunctival epithelial cells, 
HBD-2 expression has not been found or is present only at very low 
levels in normal cells. On the other hand, HBD-2 expression has been 
found to be increased in inflammatory cells related to dry-eye syn-
drome(3,4). Cathelicidins are the second group of AMPs. In humans the 
group is represented only by cathelicidin LL-37 (LL-37), a molecule 
that is expressed in corneal and conjunctival epithelial cells(8,9). This 
peptide has also been found to be expressed after corneal epithelial 
trauma and in response to some bacterial infections(10,11).
In previous studies, increased human alpha-defensin has been 
found in the tears of patients with pterygia(2), and increased ex-
pression of HBD-2 has been found in conjunctival impression 
cytological specimens of patients with dry-eye syndrome(3). To our 
knowledge, this is the first report of AMP expression in pterygium 
specimens in the literature. In this study, our aim was to investigate 
the expression of HBDs and cathelicidin in pterygium specimens, 
and whether their presence correlated with disease severity.
METHODS
InclusIon crIterIa and data collectIon
The multicenter study protocol was carried out in accordance 
with the Helsinki Declaration as revised in 2013 and was approved 
by the local ethics committee. Written informed consent was obtained 
from each subject before surgery. The unused tissue specimens 
from our previous study, entitled “GST levels in patients with ptery-
gium”(12), were included in the study. Written informed consent allowing 
their tissue to be used for investigational testing was obtained from 
each subject before surgery in the previous study(12).
PatIent detaIls and sPecImens
Twenty-six pterygium specimens and 15 control specimens 
of otherwise healthy patients who were undergoing cataract or 
strabismus surgery were included in the study. A detailed ophthal-
mic examination was performed for each patient, and pterygia 
were graded as follows: grade 1, a pterygium that did not prevent 
the visibility of episcleral vessels and had only mild inflammatory 
clinical signs; grade 2, episcleral vessels that could be partly seen 
and presence of moderate inflammatory signs; grade 3, a relatively 
thick pterygium that completely prevented the visibility of episcle-
ral vessels and had severe inflammatory signs. Excised pterygium 
tissue and 1 x 2-mm specimens of conjunctival tissue from the 
control eyes were sent to the Pathology Department for immuno-
histochemical staining. Unused specimens from the previous study 
were prepared again by the staff of the Pathology Department for 
immunohistochemical staining.
ImmunohIstochemIcal staInIng technIque
Biopsies were fixed immediately in 10% buffered formalin and 
embedded in paraffin blocks. Sections were cut 4-µm thick, and one 
section was stained with hematoxylin and eosin to assess the tissue 
morphology and tumor score. For immunohistochemistry, endo-
genous peroxidase activity was blocked by incubating the sections 
in 1% hydrogen peroxide (v/v) in methanol for 10 minutes at room 
temperature (RT). The sections were subsequently washed in distilled 
water for 5 minutes, and antigen retrieval using 0.01M citrate buffer 
(pH 6.0) in a domestic pressure cooker was performed for 3 minutes. 
The sections were transferred in 0.05M Tris-HCl (pH 7.6) containing 
0.15M sodium chloride Tris-buffered saline (TBS). After washing with 
water, the sections were incubated at RT for 10 minutes with super 
block (SHP125) (ScyTek Laboratories, Logan, UT, USA) to block nonspe-
cific background staining. The sections were then covered with the 
primary antibodies diluted 1:300 for anti-HBD-3, 1:400 for anti-HBD-2, 
1:350 for anti-HBD-1, and 1:50 for anti-LL-37 in TBS at 4°C overnight. 
Anti-HBD-1 (PA1450) was obtained from Boster Bio., Pleasanton, CA, 
United States., anti-HBD-2 (sc-59494) was from Santa Cruz Inc., Santa 
Cruz, CA, USA, USA; anti-HBD-3 (NB200-117) was from Novus Biolo-
gicals Inc., Littleton, CO, USA; and LL-37 (sc-166770) was from Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA, USA).
After washing in TBS for 15 minutes, the sections were incubated 
at RT in biotinylated link antibody (SHP125) (ScyTek Laboratories). 
Then, treatment was followed with Streptavidin/HRP complex 
(SHP125) (ScyTek Laboratories). Diaminobenzidine was used to vi-
sualize peroxidase activity in the tissues. Nuclei were lightly coun-
terstained with hematoxylin, and then the sections were dehydrated 
and mounted. Both positive and negative controls were included 
in each run. The positive controls consisted of sections of spleen 
tissues for LL-37, skin tissues for HBD-3, kidney tissues for HBD-1, and 
colon-bladder tissues for HBD-2. TBS was used in place of the primary 
antibody for negative controls.
hIstoPathologIcal evaluatIon
Light microscopy of immunohistochemically stained sections 
was performed by a pathologist and a biologist who had no knowledge 
of the patients’ clinical information. Distribution, localization, and 
characteristics of the immunostaining were recorded. Brown color 
in the cytoplasm and/or nuclei of epithelial cells of the epidermis’ 
basal layer were considered as positive staining. Scoring was also 
performed by two observers unaware of the patient data. Scoring 
differences between the observers were resolved by consensus. 
For each antibody, the intensity of the reaction (negative [-], weak 
[1+], moderate [2+], or strong [3+]) was determined to describe the 
immunoreactions.
statIstIcal analysIs
Statistical analyses were performed by using the SPSS software 
version 16 (SPSS Inc., Chicago, IL, USA). Descriptive statistical methods 
(mean, standard deviation, median, frequency, ratio, minimum, 
maximum), the Mann-Whitney U test and chi-square test were used 
in the evaluation of this study’s data. The Wilcoxon signed rank test 
was used for unequally distributed data in group comparisons. The 
Spearman correlation test was used for evaluating the data between 
groups. P values <0.05 were accepted as indicating statistical signi-
ficance.
results
BaselIne characterIstIcs
This study included 26 primary pterygium tissue specimens 
(11 males, 15 females) and 15 control (9 males, 6 females) subjects’ 
specimens. The pterygium group involved 16 grade 2 and 10 grade 
3 pterygium tissue specimens. The median age was 52 years (range, 
34-68 years) and 52 years (range, 29-64 years) in the pterygium group 
and control group, respectively. There were no significant differences 
in age and sex between groups (p=0.583, p=0.355 respectively) 
(Table 1).
ImmunohIstochemIcal staInIng results
HBD-1, HBD-2, HBD-3, and LL-37 levels in both groups are shown 
in table 1. HBD-2 levels were statistically significantly higher in the 
pterygium group than in the control group (p=0.002) (Figure 1). 
No significant differences in HBD-1 levels (p=1.00), HBD-3 levels 
(p=0.883), and LL-37 levels (p=1.00) were found between the pterygium 
group and control group (Table 1 and Figure 1).
There was no statistically significant correlation between the 
pterygium grade and HBD-2 level (r=0.090, p=0.661) (Table 2).
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me rous properties, including proliferation, cytokine production, 
chemotaxis, mast cell stimulation, and histamine release in addi-
tion to antimicrobial effects(5). Although HBD-1 was first extracted 
from human plasma, it is primarily present in epithelial tissues, 
such as airway epithelium, urogenital tissues, nasolacrimal ducts, 
and mammary glands. The expressions of HBD-2 and HBD-3 from 
various epithelial tissues appear to be stimulated by bacterial pro-
ducts and cytokines. We did not investigate HBD-4 expression(13) 
because it has only been reported to be expressed from testis and 
epi didymis(4-8). Corneal and conjunctival epithelial cells mainly 
express HBD-1 and HBD-3, whereas HBD-2 expression results from 
various stimulants. It has been found that HBD-2 expression from 
corneal epithelial cells was upregulated as a result of stimulation 
from ba c terial lipopolysaccharides via tyrosine kinase and p38 
mitogen-activated protein kinase activation(14). It has also been 
shown that HBD-2 expression was upregulated from corneal(15) and 
conjunctival(16) epithelial cells from proinflammatory cytokines, 
such as IL-1 and tumor necrosis factor-alpha.
McDermott et al. showed HBD-2 levels to increase in a cor-
neal epithelial wound healing model in an in vitro organ culture 
media(17). In two studies on patients with dry-eye syndrome with 
an inflamma tory component, HBD-2 upregulation was found in 
conjunctival impression cytological specimens(16,18). The authors 
emphasized that HBD-2 upregulation might be due to the activity 
of proinflammatory cytokines(16).
In the other subgroup of AMPs, cathelicidins, only LL-37 exists in 
humans and is expressed from corneal and conjunctival epithelial 
cells. This peptide expression is a response to corneal epithelial trau-
ma and is found to be elevated in bacterial infections because of 
Pseudomonas aeruginosa and Staphylococcus aureus. In addition, it is 
the major component of neutrophil granules, as in some defensins, 
and may be stimulated by some cytokines(7,19,20,21). Moreover, LL-37 
has properties, such as chemotaxis, histamine release from mast 
cells, dendritic cell differentiation, and cytokine release, similar to 
those of defensins(7).
In previous studies, HBD-1 and HBD-3 expressions were found 
mainly in the presence of infections, whereas HBD-2 and LL-37 
have been shown to be expressed following injury and inflamma-
tion in addition to infection(3,4,7,13-21). In our study, we did not find 
any differences in HBD-1, HBD-3, and LL-37 expressions between 
pterygium tissue and normal tissue, whereas HBD-2 expression was 
significantly higher in pterygium specimens. This finding suggests 
that HBD-2 may be associated with the inflammation involved in 
pterygium pathogenesis.
Zhou et al. found that human alpha-defensin 1 and 2 expressions 
were increased in tears of patients with pterygia. Those authors 
stated that the molecules might be related to inflammation or 
fibrovascular proliferation in pterygium(2). In our study, we assessed 
beta-defensins and cathelicidin as opposed to alpha-defensin. Our 
study is the first to compare HBD and cathelicidin expressions in 
pterygium specimens with normal tissues.
We found high-level expression of HBD-2, an AMP, in specimens 
of pterygium. HBD-2 may have an important role in pterygium patho-
genesis. Further studies are necessary to determine if HBD-2 causes 
the release of inflammatory cytokines or if inflammatory cytokines 
elicit HDB-2 expression.
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